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Abstract
Background: Individuals with high microfilarial loads of Loa loa are at increased risk of neurologic
serious adverse (SAE) events following ivermectin treatment against onchocerciasis. RAPLOA
(Rapid Assessment Procedure for loiasis), a newly developed rapid assessment procedure for
loiasis that relates the prevalence of key clinical manifestation of loiasis (history of eye worm) to
the level of endemicity of the infection (prevalence of high intensity), is a very useful tool to identify
areas at potential risk of L. loa post ivermectin treatment encephalopathy. In a perspective of
treatment decision making in areas of co-endemicity of loiasis/onchocerciasis, it would be
advantageous (both in time and cost savings) for national onchocerciasis control programmes to
use RAPLOA and the Rapid epidemiologic assessment for onchocerciasis (REA), in combination in
given surveys. Since each of the two rapid assessment tools have their own specificities, the
workability of combining the two methods needed to be tested.
Methods: We worked in 10 communities of a forest area presumed co-endemic for loiasis and
onchocerciasis in the North-West Province of Cameroon where the mass-treatment with
ivermectin had not been carried out. A four-step approach was used and comprised: (i) generating
data on the prevalence and intensity of loiasis and onchocerciasis in an area where such information
is scarce; (ii) testing the relationship between the L. loa microfilaraemia prevalence and the
RAPLOA prevalence, (iii) testing the relationship between the O. volvulus microfiladermia
prevalence and the REA prevalence, (iv) testing the workability of combining RAPLOA/REA by
study teams in which a single individual can perform the interview for RAPLOA and the nodule
palpation for REA.
Results: The microfilaraemia prevalence of loiasis in communities ranged from 3.6% to 14.3%. 6
(0.61%) individuals had L. loa microfilarial loads above 8000 mf/ml but none of them attained 30,000
mf/ml, the threshold value above which the risk of developing neurologic SAE after ivermectin
treatment is very high. None of the communities surveyed had RAPLOA prevalence above 40%.
All the communities had microfiladermia prevalence above 60%. The microfiladermia results could
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be confirmed by the rapid epidemiologic method (nodule palpation), with all the 10 communities
having REA prevalence above 20%. For the first time, this study has demonstrated that the two
rapid assessment procedures for loiasis and onchocerciasis can be carried out simultaneously by a
survey team, in which a single individual can administer the questionnaire for RAPLOA and perform
the nodule palpation for REA.
Conclusion: This study has: (i) Revealed that the Momo valley of the North West province of
Cameroon is hyperendemic for onchocerciasis, but is of lower level of endemicity for L. loa. (ii)
Confirmed the previous relationships established between RAPLOA and the L. loa microfilaraemia
prevalence in one hand and between the REA and the O. volvulus microfiladermia prevalence in
another hand (iii) Shown that RAPLOA and REA could be used simultaneously for the evaluation
of loiasis and onchocerciasis endemicity in areas targeted by the African Programme for
onchocerciasis Control for community-directed treatment with ivermectin (CDTI).
Background
For several years mass treatment with ivermectin has been
used to control onchocerciasis. The community directed
distribution of annual doses of ivermectin introduced
through the African Programme for Onchocerciasis Con-
trol (APOC) is the key component of this programme. In
this Community-directed treatment with ivermectin
(CDTI), the community itself is in charge of designing and
implementing the ivermectin distribution [1].
The mass distribution of ivermectin is always preceded by
the mapping of the target area, using rapid epidemiologic
mapping of onchocerciasis (REMO), which takes into
consideration specific spatio-epidemiological characteris-
tics of onchocerciasis (spatial distribution of vectors in
breeding sites along rivers) and the Rapid epidemiologic
assessment for onchocerciasis (REA), which is based on
the estimation of the prevalence of onchocercal nodules
in adult males using simple palpation [2]. The prevalence
of palpable nodules in adult males is almost half the prev-
alence of microfiladermia in the total population (nodule
prevalence of 20% corresponds to microfilaria prevalence
of 40–60%) [3,4]. Communities with nodule prevalence
of 20% and above are eligible for CDTI.
The large-scale distribution of ivermectin was successfully
introduced into Cameroon until neurologic serious
adverse events (SAEs) in individuals with high L. loa
microfilaraemia after ivermectin treatment were reported
[[5,6] and [7]]. The SAEs are characterized by progressive
neurologic decline and encephalopathy within a few days
of taking ivermectin. In some cases, this can result in
death or chronic disability. A recent retrospective analysis
of L. loa encephalopathy temporally related to treatment
with Mectizan® (PLERM – 'Probable' or 'Possible' L. loa
Encephalopathy temporally Related to treatment with
Mectizan®), revealed that 97% of cases so far declared in
Africa came from southern Cameroon, with 93% of them
being individuals treated with ivermectin for the first time
[8]. The main clinical signs and symptoms associated with
the PLERM are altered mental status, incontinence, diffi-
culty standing up or walking, dysarthria, fever, diarrhoea,
headache and feverishness.
These neurologic SAEs have been observed mainly in
areas where L. Loa and O. volvulus are co-endemic and this
has hampered the advancement of the mass treatment
with ivermectin in the forested areas. There was therefore
an urgent need for a rapid method to identify communi-
ties where individuals are at risk of developing neurologic
SAEs, before the implementation of mass treatment with
ivermectin.
A study carried out in Cameroon and Nigeria in 2001 sup-
ported by the UNDP/World bank/WHO Special Pro-
gramme for Research and Training in Tropical Diseases
(TDR) and APOC led to the development of a Rapid
Assessment Procedure for loiasis (RAPLOA) [9,10]. From
the results of this study it was found that communities in
which more than 40% of individuals were reported to
have experienced the sub-conjunctival migration of the
adult L. loa, confirmed by a photograph of the worm in
the eye, with the most recent episode lasting between 1–7
days, had a L. loa microfilaraemia prevalence of 20% or
above. In such communities 5% of individuals harbour
more than 8000 mf/ml and are exposed to significant
increase risk of occurrence of functional impairment after
ivermectin treatment [6]; meanwhile, 2% of them carry
more than 30,000 mf/ml and have a risk of serious neuro-
logical reactions following ivermectin treatment [5].
It is now recommended by the Mectizan® Expert Commit-
tee and the Technical Consultative Committee of APOC
(MEC/TCC) that before commencing ivermectin distribu-
tion in areas suspected, or known to be endemic for loia-
sis, RAPLOA should be undertaken to assess the
prevalence of L. loa [11].
RAPLOA is a newly developed tool and its full program-
matic implementation requires that it should beFilaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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validated, in several independent studies, in sites different
from where it was originally developed. Furthermore, it
will be advantageous, (both in time and cost savings) for
the National onchocerciasis control programmes in
Africa, to be able to carry out RAPLOA and REA using sin-
gle research teams to assess the level of endemicity of the
two infections during a given survey. Data from such sur-
veys could be used to facilitate rapid decision making to
enable the most effective treatment [12]. For instance, if
both RAPLOA and REA are negative, or if RAPLOA is pos-
itive and REA is negative, there should be no mass treat-
ment with ivermectin. If REA is positive and RAPLOA is
negative, the CDTI can be implemented safely; but if REA
is positive and RAPLOA is also positive, mass treatment
can be carried out with precautions (possibility of identi-
fying early warning signs of encephalopathy and possibil-
ity of therapeutic intervention).
Given that each of the two rapid assessment tools have
their own specificities (time factor, mode of assessment,
selection of participants and sample size requirements),
the workability of combining the two methods, needed to
be evaluated. It is in this light that we recently carried out
a study in 10 communities, selected from a forest area of
North-west Cameroon, an area which has not yet under-
gone large scale distribution of ivermectin, but which is
earmarked for CDTI and where O. volvulus and L. loa are
co-endemic. The general objective of this study was to
explore the feasibility of combining RAPLOA and REA in
a given survey by a single research team. The specific
objectives were to (i) provide information on the preva-
lence and intensity of loiasis and onchocerciasis in an area
where data was scarce, (ii) validate RAPLOA in different
sites from where it was originally developed and (iii) to
reinforce the validity of nodule palpation in an area of co-
endemicity L. loa/O. volvulus, (iv) to test the workability of
combining RAPLOA/REA by study teams in which a single
individual can perform the interview for RAPLOA and the
nodule palpation for REA.
Methods
Study site
The study was carried out in 10 villages located in the Bat-
ibo Health District, North West province of Cameroon
between March and May 2003. The villages were selected
from the Widikum subdivision located in the Momo val-
ley and included: Bifang, Ebendi, Ngalla, Ambombo, Eka,
Dinku, Oche1, Oche 2, Mbullam and Olorunti. They
extend between latitude 5° N 43 – 5° N 54 and between
longitude 9° E 41 – 9° E 44. The vegetation is a degraded
forest in which the primary rain forest has been com-
pletely replaced by the oil palm, which constitutes the
main commercial crop. The inhabitants of these villages
are mainly farmers. The climate is tropical with two sea-
sons: the rainy season which lasts from mid March to mid
November and the dry season from mid November to mid
March. The main rivers are river Momo and Tanjo, which
are tributaries of river Manyu (Figure 1).
Study population
A census was conducted in each of the villages surveyed to
estimate the population size. The study population con-
sisted of males and females aged 15 years and above who
have been resident in the village for a minimum of five
consecutive years and who have not taken antifilarial
treatment for a minimum period of one year. All eligible
members of the community and who consented to partic-
ipate were enrolled into the study. The investigation was
carried out according to a protocol approved by the ethi-
cal committee of the Research Foundation in Tropical Dis-
eases, and Environment, Buea and the Tropical Medicine
Research Station Kumba.
Conduct of the rapid assessment procedures for loiasis and 
onchocerciasis
Organization of work
A form designed to collect data was divided into four sec-
tions: the first section was for the identification of partici-
pants, the second and third sections for the collection of
RAPLOA and REA data with special reference on the start-
ing and ending time for both exercises (RAPLOA and
REA). The last section was for the parasitological results of
skin snips and thick blood films. In each community sur-
veyed, a team of three technicians moved from one house-
hold to another to register eligible participants,
administer the RAPLOA questionnaire and carried out a
Rapid epidemiological assessment (REA) by nodule pal-
pation. Each participant was then referred to the parasito-
logical post situated at the centre of the village for blood
collection and skin snipping.
Administration of RAPLOA questionnaire
The Rapid Assessment Procedure for loiasis was based on
the restricted definition of the eye worm; the past experi-
ence of eye worm, confirmed by a photograph of L. loa
adult worm in the white part of the eye and with the dura-
tion of the most recent episode being between 1 to 7 days
[9,10]. The questionnaires were administered in the Eng-
lish language and where required, interpreters from the
community assisted in the interview process according to
the RAPLOA guidelines [13]
Nodule palpation (REA)
The REA was based on nodule palpation. After undergo-
ing the RAPLOA interview, every patient was examined by
the same technician for the presence of Onchocerca nod-
ules according to previous studies [4,14].Filaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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Parasitological examinations
These involved the thick blood film to search for L. loa
microfilariae (mf) and the skin snip for O. volvulus micro-
filariae.
Thick blood film
The thick blood films were prepared from a standardised
50  µl finger prick blood collected between 10:00 and
16:00 hours using a 75 µl non-heparinised capillary tube
[15,16,10].
Collection and processing of skin snips
Two skin snips were taken with a sterile corneo-scleral
punch (Holth 2 mm) from the two iliac crests of each
patient. The skin snips were placed in two separate wells
of a microtitration plate containing 100 µl of normal
saline and covered with parafilm. Between each patient
the corneo-scleral punches were sterilised by dipping in
hypochlorous solution, followed by 70% ethanol and
finally rinsed in distilled water. After 24 hours, a drop of
2% formalin was added to each well to preserve the
microfilariae. Microfilariae were counted later using an
inverted microscope.
Expression of results
The results were entered in Epi Info (Version 6.03, 1996)
and analysed using SPSS 10.1 for Windows. The RAPLOA
prevalence was expressed as the proportion of individuals
Map of the Widikum area showing the geographical location of the villages surveyed Figure 1
Map of the Widikum area showing the geographical location of the villages surveyed.Filaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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whose answers to the questionnaire complied with the
restricted definition of eye worm. The REA prevalence was
expressed as the proportion of individuals with at least
one palpable O. volvulus nodule.
The arithmetic mean and William's mean were used to
express the intensity of the infection in study villages. The
arithmetic mean was determined as the average count of
mf/ml or mf/skin snip in each village. The William's mean
was determined as the geometric mean calculated after
having added 1 to each count [17]. The Chi-square test of
trend was used to compare prevalence between communi-
ties whereas the non-parametric Kruskal and Wallis test
was used to assess differences in the intensities of the
infection in different communities. Scatter diagrams were
plotted with the following cut-off points defined in previ-
ous studies. RAPLOA40: Prevalence of loiasis, as deter-
mined by the restricted definition of history of eye worm,
above which the risk of SAEs post ivermectin treatment is
increased. MFLOA20: Prevalence of L. loa, determined by
thick film method, above which individuals within the
community are at risk of SAEs post mass ivermectin treat-
ment. REA20: Prevalence of onchocerciasis, determined
by nodule palpation, above which the large-scale treat-
ment with ivermectin is highly desirable.
MFDONCHO60: Prevalence of onchocerciasis, deter-
mined by skin snipping, above which the large-scale treat-
ment with ivermectin is most urgent. The RAPLOA results
generated from this study were superimposed on the same
scatter plot with the original data generated during the
development of the RAPLOA study for comparison.
Results
Prevalence and intensity of loiasis
Table 1 gives the prevalence and intensity of L. loa micro-
filariae as well as the RAPLOA prevalence in study villages.
A total of 977 individuals both males and females were
enrolled in the study. The prevalence of L. loa microfilar-
iae varied from one village to another. The lowest preva-
lence (3.36%) was observed at Ebendi whereas the highest
prevalence (14.29 %) was observed at Mbullam. RAPLOA
prevalence also varied from one village to another, rang-
ing from 9.38 % in Oche 1 to 31.03% in Oche 2.
The arithmetic means of L. loa in the entire study popula-
tion ranging from 8 mf/ml of blood in Ebendi to 418.96
mf/ml of blood in Eka. In microfilaraemic individuals
they ranged from 27.67 mf/ml in Ambombo to 4468.89
mf/ml in Eka. The William's mean of microfilarial loads
also differed from one village to another, ranging from
1.18 mf/ml to 2.36 mf/ml in the entire study population
and from 1.14 mf/ml to 2.21 mf/ml in individuals with ≥
20 years.
Prevalence and intensity of onchocerciasis
The prevalence and intensity of O. volvulus as determined
by REA and Skin snips are indicated in Table 2. The prev-
alence of palpable nodules varied significantly (p < 0.001)
from one village to another. These ranged from 20.83% in
Eka to 65% in Ebendi. The prevalence of onchocerciasis
determined by the skin snips was high in all the 10 vil-
lages. It varied from 66.67% at Bifang to 95.24% at Dinku.
The William's means varied from 4.08 at Bifang to 17.38
Table 1: Prevalence and intensity (mf/ml) of L. loa determined by RAPLOA and by the Thick blood film techniques.
Prevalence (%) Intensity (mf/ml)
Village Population* No. Examined RAPLOA Thick blood 
film
Arithmetic 
Mean Mf +ve & 
-ve individuals
Arithmetic 
Mean Mf +ve 
individuals
William's 
means > 15
William's 
means > 20 
(CMFL)
Ambombo 250 49 24.49 6.12 1.63 27.67 1.22 1.25
Bifang 1889 141 21.99 3.55 81.99 2313 1.25 1.30
Mbullam 65 21 19.05 14.29 86.67 608.67 2.36 2.21
Dinku 516 159 30.82 10.69 1.3.77 970.79 1.83 2.02
Ebendi 260 120 13.33 3.36 8.00 240.00 1.18 1.14
Eka 1079 96 14.58 9.38 418.96 4468.89 1.87 1.96
Ngalla 765 138 16.67 7.25 232.46 3208.00 1.53 1.55
Oche 1 83 32 9.38 12.50 293.13 2345.00 2.08 2.13
Oche 2 77 29 31.03 10.34 13.10 126.67 1.609 1.93
Olorunti 707 192 20.31 4.69 119.27 2544.44 1.39 1.40
Total 5691 977
Average 20.47 6.86 139.08 2028.06 1.50 1.53
* Total population recorded during a census conducted in study villages; CMFL: Community microfilarial load. Mf +ve: Microfilaraemic, MF -ve: 
amicrofilaraemicFilaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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at Dinku. In individuals with age ≥  20 years, it ranges from
4.19 mf/ml in Bifang to 18.58 in Mbullam.
Knowledge of eye worm, attitude and practice in study 
communities
The eye worm was well known in these communities. In
Bifang, Ebendi, Ngalla, Ambombo and Eka it is called
"Embele", in Dinku, Oche 1, Oche 2 and Mbullam it is
called "ntembele". In Olorunti it is called "etembele".
These names were generally descriptive. It was noticed
that communities have "Eye Worm specialists", who are
capable of removing adult L. loa as they migrate across the
subconjunctiva.
Relationship between the RAPLOA and L. loa 
microfilaraemia prevalence
Figure 2a summarises the relationship between the parasi-
tological prevalence and RAPLOA prevalence. All the vil-
lages surveyed had RAPLOA prevalences less than 40%. L.
loa microfilaraemia prevalences were less than 20 % in all
the communities. The parasitological prevalences are in
agreement with the RAPLOA predictions. These results fit-
ted very well when superimposed on the original data
generated during the development of RAPLOA (Figure 3).
Relationship between the REA prevalence and 
microfiladermia prevalence
Figure 2b summarises the relationship. All the communi-
ties surveyed had REA prevalence above 20% and preva-
lence of microfiladermia greater than 60%. On average,
the skin snip prevalences (81.37%) were nearly twice as
high as the REA prevalences (45.04%). There is good
agreement between the two sets of prevalence, indicating
that the study area has high endemicity for onchocerciasis.
Some communities with REA close to 20% had high
microfiladermia prevalence (> 70 %).
Combining RAPLOA and REA
This study has revealed that an examiner, using a single
recording form with specific sections for REA and
RAPLOA can take 8–10 minutes to examine an individual
for loiasis and onchocerciasis in tandem. With three tech-
nicians performing the two tasks at the household's level,
it took on average 4 hours to cover one community with
a sample size of 80 people per day. Not-withstanding the
difficulties of movement in the study area due to bad
roads or lack of passable roads, we could examine during
this survey on average two communities with an average
sample size of 80 individuals per day. In the village Olu-
runti, working from 10:00 AM to 3:00 PM we examined
192 individuals. Figure 2c summarises the relationship
between REA (%) and RAPLOA (%). All the communities
surveyed had REA above 20% and RAPLOA less than 40%
indicating that CDTI could be conducted within them
safely.
Discussion
Endemicities of onchocerciasis and loiasis in the study area
This study has revealed that the Widikum health area sit-
uated in the Momo valley is an area hyperendemic for
onchocerciasis. All the communities surveyed had
microfiladermia prevalences above 60%. The intensity of
infection as expressed by the arithmetic means and the
William geometric means were relatively low. None of the
communities had an arithmetic mean above 100 mf/skin
snip. This lack of close relationship between the
Table 2: Prevalence and Intensity of O. volvulus determined by REA and Skin snip
Prevalence (%) Intensity (mf/Skin snip)
Village Population* No. Examined REA Skin snip Arithmetic Mean 
Mf +ve & -ve 
individuals
Arithmetic Mean 
Mf +ve individuals
William's means ≥  
15
William's means ≥  
20 (CMFL)
Ambombo 250 49 40.82 69.39 14.57 21.00 5.07 4.76
Bifang 1889 141 38.30 66.67 12.54 18.80 4.06 4.19
Mbullam 65 21 23.81 95.24 65.26 68.52 13.38 14.60
Dinku 516 159 54.72 94.34 32.45 34.40 17.31 18.58
Ebendi 260 120 65.00 85.83 19.70 22.95 7.76 7.82
Eka 1079 96 20.83 72.92 14.13 19.37 5.24 5.69
Ngalla 765 138 56.52 76.09 18.45 24.25 6.85 7.70
Oche 1 83 32 21.88 87.50 11.25 12.86 5.41 6.52
Oche 2 77 29 55.17 86.21 28.07 32.56 10.53 10.49
Olorunti 707 192 39.06 86.46 31.68 36.43 10.57 10.89
Total 5691 977
Average 45.04 81.37 23.06 28.31 7.99 8.22
* Total population recorded during a census conducted in study villages, CMFL : Community microfilarial load ; Mf +ve: Microfiladermic, MF -
ve: amicrofiladermic individuals & -veFilaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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prevalence and intensity of infection could be explained
by the existence of passive treatment with ivermectin in
the area. Even though the CDTI was not in place in this
area at the time of this survey, it could be noticed that
almost 25% of individuals involved in the study stated
they had taken ivermectin 2 to 3 years before the study
(unpublished observations). Since the effect of ivermectin
can last up to 3 years, this could have contributed to the
reduction of microfilarial density. Indeed, the Momo val-
ley is close to the South-West Province where the CDTI
has been going on for over 5 years and some people
admitted getting treatment from the South-West project.
The infection level of L. loa was relatively low. None of the
communities surveyed had L. loa microfilariae prevalence
(mf-prevalence) greater than 20%. According [16], for
practical purposes, communities with L. loa mf-prevalence
less than 10% should be considered as hypo endemic and
communities with mf-prevalence between 10% and 20%
should be considered as meso-endemic. The intensity of
L. loa infection in microfilaraemic patients as expressed by
the arithmetic mean did not exceed 4500 mf/ml, contrast-
ing with the observations made in the Lekié division [16],
Central Province of Cameroon, where some communities
examined for L. loa had intensities up to 22791 mf/ml of
blood. It should be noted that the Lékié division is the
area where most of the cases of Loa-related encephalopa-
thies were observed. The results of this study also contrast
with the observations made in the Ntem valley (a forested
savannah zone in the North-west province of Cameroon)
a: Relationship between the RAPLOA and L. loa microfilaraemia prevalences Figure 2
a: Relationship between the RAPLOA and L. loa microfilaraemia prevalences. Dotted lines represent the thresholds levels 
above which there is increased risk of neurologic SAEs. b Relationship between the REA and the microfiladermia prevalences. 
Dotted lines represent the thresholds levels above which mass treatment with ivermectin is most urgent (microfiladermia) or 
highly desirable (REA). c Relationship between RAPLOA and REA prevalences. A: Large-scale treatment with low risk of neu-
rologic SAEs; B: Large scale treatment with high risk of neurologic SAEs; C: No large-scale treatment with ivermectin D: No 
large-scale treatment with ivermectin. Dotted lines represent the thresholds levels above which the risk of neurologic SAEs is 
high
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[17], where in a survey carried out in10 communities, L.
loa  intensities (arithmetic mean of total number of
patients examined) of up to 9995 mf/ml were observed in
some communities. However, the findings of the present
study were very similar to the observations made in the
forest villages of south-west Province of Cameroon [18].
Relationship between the Rapid assessment procedure 
prevalences and the parasitological prevalences
– RAPLOA prevalence versus Loa-microfilaria prevalence
None of the communities surveyed had RAPLOA preva-
lence above 40% (threshold value established by the
RAPLOA development study) [10]. Also none of the com-
munities had L. loa microfilareamia above 20% (thresh-
old prevalence above which more than 5% of adults living
in the community are at risk of adverse-related responses
with ivermectin) [16]. There is therefore a good agreement
between the results from the Thick blood film technique
and the results from RAPLOA, since the two sets of find-
ings have reached the same conclusion that the study area
is not hyperendemic for loiasis and that the risk of serious
adverse events after ivermectin treatment may be very low
in these communities. In this light, this independent
study has validated the rapid assessment procedure for
loiasis (RAPLOA) in predicting the level of endemicity of
loiasis and the risk of neurologic serious adverse events
after ivermectin treatment in a given area. It may not be
necessary therefore to strengthen monitoring by a medical
team, after a campaign of mass treatment with ivermectin.
Indeed, a mass treatment with ivermectin, carried out in
Relationship between RAPLOA prevalence and Loa microfilaraemia: (▲ ) New data, (o) Data generated during RAPLOA  development Figure 3
Relationship between RAPLOA prevalence and Loa microfilaraemia: (▲ ) New data, (o) Data generated during RAPLOA 
development.Filaria Journal 2005, 4:2 http://www.filariajournal.com/content/4/1/2
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the 10 communities and involving some 4000 eligible
individuals did not show any neurologic serious adverse
events related to ivermectin treatment (unpublished data)
- REA prevalence versus Onchocerca microfiladermia 
prevalence
All the villages surveyed had prevalences of palpable nod-
ules above 20% (threshold defined as proportion above
which a community should be included in the CDTI pro-
gramme). These REA results were confirmed by skin snip
results; all the communities examined had microfilader-
mia prevalences above 60%. These two sets of results con-
firm that the Momo valley, characterized by important
fast flowing rivers with excellent breeding sites for
Simulium damnosum s.l, is an area of high endemicity of
onchocerciasis. The results of this study are in agreement
with previous studies [4,14] and constitute a further vali-
dation of the REA to predict the level of endemicity of
onchocerciasis. Although the validation of REA has been
done before, this is the first time such validation is being
done in an area of co-endemicity of onchocerciasis/loia-
sis.
Combining REA and RAPLOA and its implications for the 
onchocerciasis control programmes' activities in Africa
The recent MEC/TCC recommendation that before intro-
ducing the mass distribution of ivermectin for
onchocerciasis control in an area suspected or known to
be endemic for loiasis, RAPLOA should be carried out to
assess the prevalence of L. loa, has necessitated the evalu-
ation of the possibility of combining REA and RAPLOA,
the two assessment procedures for onchocerciasis and loi-
asis endemicity.
The two tools have several similarities in their methodo-
logical approaches: they are carried out on individuals
(adults or nearly-adults) of both sexes, who have been res-
ident in a community for a long period of time, their sam-
ple size requirements are not conflicting, the exercises of
interview and nodule palpation are very simply to exe-
cute. However, the question of whether a single examiner
could perform the two tasks in succession, with a high
level of efficiency, as measured by the ratio output/time,
arose. In other words, how long can it take an examiner to
assess a patient for the two filarial infections? This study
has shown that it can take 8 to 10 minutes. By extrapolat-
ing this basic result to a survey team made up of 5 individ-
uals who can carry out the two procedures in tandem, it is
possible to examine 80 subjects in less than three hours.
This will allow a good team to evaluate 3–4 communities
per day under optimum conditions (good mobilisation,
community accessibility). Indeed, we were able in the
present study to examine 192 individuals in the village of
Olurunti from 10:00 AM to 3: 00 P.M with a team of 3
persons.
The possibility of simultaneously carrying out at the com-
munity level RAPLOA and REA for assessing loiasis and
onchocerciasis prevalences will have a great impact on the
planning and implementation of activities of onchocer-
ciasis control programmes in areas of co-endemicity with
loiasis. There will be a gain both in time and in cost sav-
ings, since a single well organized survey in a given area
will be enough to assess the level of endemicity of the two
filarial species. More important will be the fact that, data
from such surveys could be used rapidly in treatment deci-
sion making. For instance, if both RAPLOA and REA are
negative (prevalence <40% and <20% respectively), or if
RAPLOA is positive (prevalence >40%) and REA is nega-
tive, there should be no mass treatment with ivermectin.
If REA is positive (prevalence >20%) and RAPLOA is neg-
ative, the CDTI can be implemented safely. But if REA is
positive and RAPLOA is also positive, mass treatment can
be carried out following MEC/TCC guidelines. The results
of this combined survey RAPLOA/REA clearly indicate
that the CDTI could be implemented safely in the Momo
valley of the North-west province of Cameroon. Indeed, a
CDTI project, which is now in its second year of activities
in this area, has not so far registered any neurologic SAE
(unpublished data).
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